KV agrees to FDA plan for resuming work

KV Pharmaceuticals said it has entered a consent decree with the FDA that provides for KV's return to manufacturing and distribution of its products, provided it satisfies a series of requirements. As you know, KV stopped making products in January and cut its workforce in half last month. Release